Abstract

The dystroglycan (DG) complex plays a pivotal role for the stabilization of muscles in Metazoa. It is formed by two subunits, extracellular α-DG and transmembrane β-DG, originating from a unique precursor via a complex post-translational maturation process. The α-DG subunit is extensively glycosylated in sequential steps by several specific enzymes and employs such glycan scaffold to tightly bind basement membrane molecules. Mutations of several of these enzymes cause an alteration of the carbohydrate structure of α-DG, resulting in severe neuromuscular disorders collectively named dystroglycanopathies. Given the fundamental role played by DG in muscle stability, it is biochemically and clinically relevant to investigate these post-translational modifying enzymes from an evolutionary perspective. A first phylogenetic history of the thirteen enzymes involved in the fabrication of the so-called 'M3 core' laminin-binding epitope has been traced by an overall sequence comparison approach, and interesting details on the primordial enzyme set have emerged, as well as substantial conservation in Metazoa. The optimization along with the evolution of a well-conserved enzymatic set responsible for the glycosylation of α-DG indicate the importance of the glycosylation shell in modulating the connection between sarcolemma and surrounding basement membranes to increase skeletal muscle stability, and eventually support movement and locomotion.

Highlights

  • Dystroglycan (DG) is an extracellular matrix (ECM) protein complex with a wide tissue distribution, that ranges from skeletal, cardiac and smooth muscle to the central and peripheral nervous systems [1,2]

  • O-mannosylation, that was originally discovered in fungi [74,75], is known to be conserved from bacteria to humans [76] and multiple O-man glycosylation pathways have been found in eukaryotes [14]

  • O-mannosylation as such is not characteristic of plants [14], very good hits with POMT1 and POMT2 have been found in Quercus suber (XP_023912063.1), Carpinus fangiana (KAB8356666.1) or Rhodamnia argentea (XP_030536296.1)

Read more

Summary

Introduction

Dystroglycan (DG) is an extracellular matrix (ECM) protein complex with a wide tissue distribution, that ranges from skeletal, cardiac and smooth muscle to the central and peripheral nervous systems [1,2]. DG is encoded by the DAG1 gene and translated from a single mRNA as a precursor which undergoes post-translational modifications that include extensive decoration with carbohydrates and processing into two subunits: the highly glycosylated extracellular α-DG and the transmembrane β-DG [3]. Α-DG acts as a receptor for ECM proteins containing laminin-globular (LG) domains such as laminin and agrin, among others [4]. The carbohydrate moieties of α-DG are mainly concentrated within the elongated central mucin-like region that separates two-terminal globular domains [7]. Alterations in the glycosylation shell of α-DG (i.e. hypoglycosylation) can induce muscular dystrophies, referred to as primary or secondary dystroglycanopathies (hereinafter DGpathies), which present themselves with phenotypes that royalsocietypublishing.org/journal/rsob Open Biol. 11: 210104

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call